What Does
LUPRON DEPOT Offer?

Anthony, age 57
IT specialist, dog shelter
volunteer, single

LUPRON DEPOT offers a proprietary delivery system and formulation designed with you and your patient’s experience in mind.

Delivery System Innovations

*Mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.

Review Product Features

An at-a-glance review of selected features of currently available hormone suppression therapies.

DOSING OPTIONS

LUPRON DEPOT

(leuprolide acetate for depot suspension)1

  • 45 mg every 6 months
  • 30 mg every 4 months
  • 22.5 mg every 3 months
  • 7.5 mg every month

Eligard®

(leuprolide acetate for injectable suspension)4

  • 45 mg every 6 months
  • 30 mg every 4 months
  • 22.5 mg every 3 months
  • 7.5 mg every month

Trelstar®

(triptorelin pamoate for injectable suspension)5

  • 22.5 mg every 24 weeks
  • 11.25 mg every 12 weeks
  • 3.75 mg every 4 weeks

Zoladex®

(goserelin acetate implant)6,7

  • 10.8 mg every 12 weeks
  • 3.6 mg every 28 days

Vantas®

(histerelin implant) subcutaneous implant8

  • 50-mg implant every 12 months

Firmagon®

(degarelix for injection)9

  • Starting dose of 240 mg given as two 120-mg injections, followed by one 80-mg maintenance dose given every 28 days

No conclusions regarding the comparative safety or efficacy can be made from this table. Route of administration varies. Eligard, Zoladex, Trelstar, Vantas, Firmagon, SafeSystem, and MixJect are trademarks of their respective owners.

SYRINGE TYPE
NEEDLE GAUGE
STORAGE
BUILT-IN SAFETY MECHANISM
DOSING OPTIONS
SYRINGE TYPE
NEEDLE GAUGE
STORAGE
BUILT-IN SAFETY MECHANISM

 

Lyophilized Microsphere Technology

LUPRON DEPOT is formulated with lyophilized microsphere technology, gradually releasing active drug from each microsphere over time.1,11

  • The active drug, leuprolide acetate, is embedded in microcapsules composed of a biodegradable, hydrophobic polymer to overcome high solubility in body fluids and rapid excretion in vivo1,11
  • Leuprolide is released in two phases in vivo: diffusion and bioerosion, gradually releasing active drug from each microsphere over time1,11

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

  • LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT.
  • LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:
    • Transient worsening of symptoms, or additional signs and symptoms of prostate cancer.
    • Temporary increase in bone pain in a small number of patients, which can be managed symptomatically.
    • Isolated cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications. Observe patients with vertebral metastasis and/or urinary tract obstruction closely.
  • Hyperglycemia and increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in men receiving a GnRH agonist, and manage hyperglycemia or diabetes.
  • An increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists in men, although the risk appears low. Evaluate the risks carefully, including cardiovascular risk factors, when determining prostate cancer treatment. Patients receiving a GnRH agonist should be monitored for signs and symptoms of cardiovascular disease and managed appropriately.
  • Androgen deprivation therapy (ADT) may prolong the QT/QTc interval. Consideration should be given to whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities and consider periodic monitoring of electrocardiograms and electrolytes.
  • Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy, including patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications associated with convulsions, such as bupropion and SSRIs. Convulsions have also been reported in the absence of any of the conditions mentioned above.
  • Periodic monitoring of serum testosterone and PSA levels is recommended.
  • LUPRON DEPOT may cause fetal harm when administered to a pregnant woman. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
  • LUPRON DEPOT may impair fertility in males of reproductive potential.
  • In controlled clinical trials of advanced prostatic cancer patients receiving LUPRON DEPOT, the following adverse events occurred in >10% of patients:
    • LUPRON DEPOT 7.5 mg for 1‑month administration: hot flashes/sweats, general pain, edema, urinary disorders, GI disorders, and respiratory disorders.
    • LUPRON DEPOT 22.5 mg for 3‑month administration: hot flashes/sweats, general pain, testicular atrophy, GI disorders, urinary disorders, injection site reactions, and joint disorders.
    • LUPRON DEPOT 30 mg for 4‑month administration: hot flashes/sweats, injection site reactions, general pain, edema, urinary disorders, joint disorders, GI disorders, asthenia, flu syndrome, skin reactions, and headache.
    • LUPRON DEPOT 45 mg for 6‑month administration: hot flush/flushing, upper respiratory tract infection/influenza-like illness, injection site pain/discomfort, and fatigue/lethargy.

US-LUPR-190307

Please see accompanying Full Prescribing Information.

References

  1. LUPRON DEPOT [package insert]. North Chicago, IL: AbbVie Inc; 2019.

  2. Data on file. AbbVie Inc. ABVRRTI63636.

  3. Nygren O, Olofsson E, Johannson L. NIOSH definition of closed-system drug-transfer devices. Ann Occup Hyg. 2009;53(5):549. doi:10.1093/annhyg/mep030.

  4. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc; 2019.

  5. Trelstar [package insert]. Madison, NJ: Allergan USA, Inc; 2018.

  6. Zoladex 3.6 mg [package insert]. Lake Forest, IL: TerSera Therapeutics LLC; 2019.

  7. Zoladex 10.8 mg [package insert]. Lake Forest, IL: TerSera Therapeutics LLC; 2019.

  8. Vantas [package insert]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; 2017.

  9. Firmagon [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2016.

  10. Dosing and administration. Trelstar website. http://www.trelstar.com/dosing-and-administration. Accessed October 8, 2019.

  11. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28(1):43-70. doi:10.1016/S0169-409X(97)00050-1.

  12. Data on file. AbbVie Inc. LuproLink clinic count. 2018.

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT. LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT. LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT. LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT. LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:

Indication1

LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.

Important Safety Information1

  • LUPRON DEPOT is contraindicated in patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT.
  • LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:
    • Transient worsening of symptoms, or additional signs and symptoms of prostate cancer.
    • Temporary increase in bone pain in a small number of patients, which can be managed symptomatically.
    • Isolated cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications. Observe patients with vertebral metastasis and/or urinary tract obstruction closely.
  • Hyperglycemia and increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in men receiving a GnRH agonist, and manage hyperglycemia or diabetes.
  • An increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists in men, although the risk appears low. Evaluate the risks carefully, including cardiovascular risk factors, when determining prostate cancer treatment. Patients receiving a GnRH agonist should be monitored for signs and symptoms of cardiovascular disease and managed appropriately.
  • Androgen deprivation therapy (ADT) may prolong the QT/QTc interval. Consideration should be given to whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities and consider periodic monitoring of electrocardiograms and electrolytes.
  • Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy, including patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications associated with convulsions, such as bupropion and SSRIs. Convulsions have also been reported in the absence of any of the conditions mentioned above.
  • Periodic monitoring of serum testosterone and PSA levels is recommended.
  • LUPRON DEPOT may cause fetal harm when administered to a pregnant woman. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
  • LUPRON DEPOT may impair fertility in males of reproductive potential.
  • In controlled clinical trials of advanced prostatic cancer patients receiving LUPRON DEPOT, the following adverse events occurred in >10% of patients:
    • LUPRON DEPOT 7.5 mg for 1‑month administration: hot flashes/sweats, general pain, edema, urinary disorders, GI disorders, and respiratory disorders.
    • LUPRON DEPOT 22.5 mg for 3‑month administration: hot flashes/sweats, general pain, testicular atrophy, GI disorders, urinary disorders, injection site reactions, and joint disorders.
    • LUPRON DEPOT 30 mg for 4‑month administration: hot flashes/sweats, injection site reactions, general pain, edema, urinary disorders, joint disorders, GI disorders, asthenia, flu syndrome, skin reactions, and headache.
    • LUPRON DEPOT 45 mg for 6‑month administration: hot flush/flushing, upper respiratory tract infection/influenza-like illness, injection site pain/discomfort, and fatigue/lethargy.

US-LUPR-190307